Beacon Investment Advisory Services Inc. Acquires 6,429 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Beacon Investment Advisory Services Inc. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 86,661 shares of the biopharmaceutical company's stock after purchasing an additional 6,429 shares during the quarter. Beacon Investment Advisory Services Inc.'s holdings in Gilead Sciences were worth $9,710,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences in the first quarter valued at $25,000. Goodman Advisory Group LLC purchased a new stake in shares of Gilead Sciences in the first quarter valued at $29,000. Core Alternative Capital lifted its holdings in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC lifted its holdings in shares of Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. lifted its holdings in shares of Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 100 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Morgan Stanley raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $111.38.

Gilead Sciences Trading Up 1.0%

GILD traded up $1.15 during trading on Wednesday, reaching $111.32. 359,366 shares of the company's stock were exchanged, compared to its average volume of 7,620,724. The company's fifty day moving average price is $108.81 and its 200-day moving average price is $105.35. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a fifty-two week low of $70.78 and a fifty-two week high of $119.96. The firm has a market capitalization of $138.47 billion, a PE ratio of 23.44, a P/E/G ratio of 0.70 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the business earned ($1.32) EPS. The business's quarterly revenue was down .3% compared to the same quarter last year. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total value of $333,090.00. Following the completion of the sale, the insider owned 117,168 shares in the company, valued at $13,009,163.04. This represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,000 shares of company stock worth $7,844,775 over the last quarter. 0.27% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.